Clonal Evolution

Burns, M. B., Lackey, L., Carpenter, M. A., Rathore, A., Land, A. M., Leonard, B., Refsland, E. W., Nandakumar, J., Temiz, N. A., Donohue, D. E., McDougle, R. M., Brown, W. L., Law, E. K., & Harris, R. S. (2013). APOBEC3B is an enzymatic source of mutation in breast cancer. Nature, 494(7437), 366–370.

Properties1
tagsmutational-processes, primary-research, medium-evidence

6 min read

Burns et al. (2013) — APOBEC3B is an enzymatic source of mutation in breast cancer

Bibliographic Reference

Burns, M. B., Lackey, L., Carpenter, M. A., Rathore, A., Land, A. M., Leonard, B., Refsland, E. W., Nandakumar, J., Temiz, N. A., Donohue, D. E., McDougle, R. M., Brown, W. L., Law, E. K., & Harris, R. S. (2013). APOBEC3B is an enzymatic source of mutation in breast cancer. Nature, 494(7437), 366–370. DOI: 10.1038/nature11881.

Core Argument

APOBEC3B (A3B) is a significant endogenous source of enzymatic C-to-T mutation in breast cancer. Its upregulation in tumor cells generates uracil lesions in genomic DNA, producing both the characteristic TC→TT mutation signature and increased overall mutational load. A3B-catalyzed DNA deamination provides “genetic fuel” for tumor evolution by broadly affecting multiple pathways and phenotypes, contributing to the heterogeneity upon which selection and therapy resistance depend.

Methods

  • Cell lines: 38 breast cancer cell lines from ATCC; MDA-MB-453, MDA-MB-468, and HCC1569 as representative A3B-high lines
  • Expression analysis: RT-qPCR for all 11 APOBEC family members in cell lines and 52 matched tumor/normal breast tissue pairs
  • Subcellular localization: A3B-eGFP and HA-tagged constructs; live-cell imaging
  • Deaminase activity: Fluorescence-based DNA C-to-U assay on nuclear extracts; dinucleotide preference profiling (TC, CC, GC, AC)
  • Genomic uracil quantification: UPLC-MS/MS with heavy-labeled uracil internal standard in A3B-high vs. shA3B-knockdown cells
  • Mutation rate: TK fluctuation analysis (TK+ → TK−) comparing shControl vs. shA3B
  • 3D-PCR: Differential denaturation PCR to detect C-to-T mutations at TP53, c-MYC, and CDKN2B loci
  • Overexpression phenotyping: Doxycycline-inducible A3B-eGFP, A3B-E68A-E255Q (catalytic dead), A3A-eGFP, A3A-E72A in HEK293 T-REx cells; cell cycle, viability, γ-H2AX foci, comet assays
  • Bioinformatic analysis: Public sequencing data from breast (Nik-Zainal 2012, Stephens 2012, TCGA 2012), melanoma (Wei 2011), and liver (Zhang 2011) tumors; local sequence context analysis of C-to-T mutations
  • Statistical tests: Wilcoxon signed-rank (matched tissues), Mann-Whitney U (unmatched comparisons)

Key Findings

  1. A3B is selectively upregulated in breast cancer. A3B mRNA was upregulated by ≥3 SD above controls in 28/38 breast cancer cell lines and in 20/52 primary breast tumors relative to patient-matched normal tissue. No other APOBEC family member showed preferential tumor expression. (Fig. 1a, Fig. 4a)

  2. Endogenous A3B localizes to the nucleus and deaminates genomic DNA with a TC preference. A3B-eGFP showed nuclear localization in breast cancer lines. Nuclear extracts exhibited robust DNA C-to-U editing activity that was ablated by A3B knockdown. The endogenous enzyme preferred the TC dinucleotide context, matching the motif observed in A3B-associated retroviral hypermutation. (Fig. 1b–d)

  3. A3B produces 30,000–60,000 genomic uracils per haploid genome. Mass spectrometry quantification revealed A3B-dependent uracil loads of 10–20 uracils per Mbp in A3B-high cells, decreasing 30–70% upon A3B knockdown. Actual levels may be higher due to concurrent repair. (Fig. 2a–b)

  4. A3B-high cells accumulate 3-to-5-fold more mutations. TK fluctuation analysis showed that HCC1569 and MDA-MB-453 cells with endogenous A3B upregulation accumulated significantly more drug-resistance mutations than A3B-knockdown controls. 3D-PCR confirmed C-to-T hypermutation at TP53 and c-MYC loci in A3B-high cells, with locus-specific susceptibility (CDKN2B was less mutable). (Fig. 2c–d)

  5. A3B overexpression triggers DNA damage, cell cycle arrest, and C-to-T mutations. Inducible A3B caused γ-H2AX focus formation, DNA fragmentation (comet assay), delayed cell cycle arrest, abnormal multinucleate cell formation, and eventual cell death. All phenotypes required catalytic activity (glutamate mutant was inactive). In contrast, A3A overexpression caused rapid S-phase arrest and acute cytotoxicity. (Fig. 3a–e)

  6. A3B expression correlates with C-to-T mutation load in primary breast tumors. In TCGA breast tumor data, C-to-T mutations comprised ~40% of all substitutions (intermediate between UV-driven melanoma at ~80% and spontaneous liver tumors at ~20%). The C-to-T trinucleotide context matched A3B’s in vitro preference (TpC > CpC > GpC = ApC). A3B expression level correlated positively with C-to-T mutation count (p < 0.0001), total base substitution count, and TP53 inactivation. High-A3B tumors carried approximately twice as many mutations as low-A3B tumors — an estimated 10 C-to-T and 30 total mutations per exome (approximately 1,000 and 3,000 per genome) attributable to A3B. (Fig. 4c–g)

  7. A3B is proposed as a therapeutic target. Given its non-essential nature (common homozygous deletion polymorphism with no known phenotype), A3B inhibition may decrease the rate of tumor evolution and stabilize the targets of existing therapeutics by reducing the mutational substrate available for selection. (Discussion)

Concepts Introduced or Used

  • APOBEC3B (A3B): Nuclear DNA cytosine deaminase; endogenous mutator in breast cancer; TC dinucleotide preference; non-essential gene with common deletion polymorphism
  • Enzymatic DNA deamination: A3B-catalyzed C-to-U conversion in genomic DNA as a source of mutation distinct from replication errors
  • Mutational signature: TC→TT (or TC→TU→T) as the characteristic APOBEC-associated mutation pattern; local sequence context analysis linking in vitro deamination preference to in vivo tumor mutation spectra
  • Kataegis: Referenced as phenomenon of clustered mutations (Nik-Zainal 2012, Stephens 2012); A3B proposed as candidate enzyme
  • Mutator hypothesis: Loeb (1974) — cancer initiated by mutations in genes that control mutation rate; A3B as an enzymatic mutator
  • Tumor heterogeneity: A3B as a dominant underlying factor generating the mutational diversity upon which selection acts

Entities Referenced

  • apobec3b — A3B; the primary subject
  • apobec3a — A3A; myeloid-specific, more acutely cytotoxic, distinct from A3B
  • tp53 — TP53; inactivation correlates with high A3B expression; may be required to bypass A3B-triggered DNA damage checkpoints
  • aid — AID/AICDA; B-cell-specific deaminase in somatic hypermutation and class-switch recombination
  • breast-cancer — Primary disease context
  • c-myc — MYC; one of the genomic loci showing A3B-dependent C-to-T hypermutation

Limitations (as stated by authors)

  • Tumor A3B levels are underestimates because tumor specimens contain varying fractions of non-A3B-expressing normal cells, and some matched ‘normal’ samples may be contaminated by tumor cells
  • Other base substitution patterns beyond C-to-T may reflect downstream processing of U/G mispairs by repair enzymes; the full mutational spectrum attributable to A3B is likely broader than TC→TT alone
  • A3B’s relationship with other oncogenes and tumor suppressors beyond TP53 requires further investigation
  • The study was conducted in breast cancer; whether A3B plays similar roles in other cancer types requires additional work (addressed by companion paper in Nature Genetics)

Relevance to Clonal Evolution

This paper provides the mechanistic foundation for APOBEC mutagenesis as a driver of clonal diversity in cancer. By demonstrating that a single endogenous enzyme can account for a substantial fraction of the mutational burden in breast cancer, it identifies A3B as a molecular engine of the variation upon which clonal evolution depends. The finding that A3B-high tumors carry approximately twice as many mutations directly links enzymatic mutagenesis to the mutational substrate available for selection. The proposal that A3B inhibition could “decrease the rate of tumor evolution” frames APOBEC as a potential therapeutic vulnerability in the evolutionary process itself — not targeting a specific mutation, but reducing the rate at which new mutations arise. For the clonal evolution framework, this paper establishes that mutational processes are not merely background noise: they are enzymatically driven, variable between tumors, and potentially druggable.

Graph View

Backlinks